-

AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the fourth quarter and fiscal year 2025 before the market open on Tuesday, July 15, 2025. The Company’s management will host a conference call at 8:00 am ET the same day to discuss the results.

To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international). This conference call will also be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available, until Tuesday, July 15, 2025 at 11:59 PM ET. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13754203.

About AngioDynamics, Inc.

AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.

The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.

Contacts

Investors:
AngioDynamics, Inc.
Stephen Trowbridge, Executive Vice President & CFO
(518) 795-1408

AngioDynamics, Inc.

NASDAQ:ANGO

Release Versions

Contacts

Investors:
AngioDynamics, Inc.
Stephen Trowbridge, Executive Vice President & CFO
(518) 795-1408

More News From AngioDynamics, Inc.

AngioDynamics to Present at the Leerink Partners Global Healthcare Conference

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, will present at the Leerink Partners Global Healthcare Conference on Monday, Mar. 9, 2026. The Company's presentation will begin at 1:40 p.m. (ET). A live we...

AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced expanded European indications for its NanoKnife System to include soft tissue ablation for tumors of the liver, pancreas, kidney, and prostate, including in patients with intermediate-risk prostate cancer. The expan...

AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, and The PERT Consortium®, a leading multidisciplinary organization dedicated to improving pulmonary embolism (PE) care, today announced the launch of the ALPHA-PE Research Fund, an investigator-led initiative supporting independent...
Back to Newsroom